Skip to content

Asset turnover at other companies

Merck & Co. logo
Merck & Co.MRK
0.5×0.0×
Amgen logo
AmgenAMGN
0.4×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.4×0.0×
Eli Lilly logo
Eli LillyLLY
0.7×+0.1×
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Calculated from NewAmsterdam Pharma Company’s reported figures.

Based on trailing twelve months.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's asset turnover?
NewAmsterdam Pharma Company (NAMS) reported asset turnover of 0× in Q1 2026.
How has NewAmsterdam Pharma Company's asset turnover changed year-over-year?
NewAmsterdam Pharma Company's asset turnover decreased by 59.6% year-over-year, from 0.1× to 0×.
What is the long-term trend for NewAmsterdam Pharma Company's asset turnover?
Over 2 years (2023 to 2025), NewAmsterdam Pharma Company's asset turnover has grown at a -10.2% compound annual growth rate (CAGR), from 0× to 0×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.